Fujian Haixi New Drug Creation Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Fuzhou, Fujian. The company went IPO on 2025-10-20. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The firm mainly operates its businesses in the domestic market.
02637.HK stock price ended at $161.5 on 星期四, after rising 3.59%
On the latest trading day Jan 15, 2026, the stock price of 02637.HK rose by 3.59%, climbing from $155.80 to $161.50. During the session, the stock saw a volatility of 3.85%, with prices oscillating between a daily low of $155.70 and a high of $161.70. Notably, trading volume dropped by 38.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 108.5K shares were traded, equating to a market value of approximately $12.7B.